UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

Cancer treatment reviews, 2018-01, Vol.62, p.18-28

2018

Link zum Volltext

Verfügbarkeit prüfen

Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy

Gynecologic oncology, 2014-11, Vol.135 (2), p.231-238

2014

Link zum Volltext

Verfügbarkeit prüfen

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer

Cancer treatment reviews, 2011-10, Vol.37 (6), p.422-430

2011

Link zum Volltext

Verfügbarkeit prüfen

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

Annals of oncology, 2011-01, Vol.22 (1), p.207-214

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

European journal of cancer (1990), 2016-02, Vol.54, p.57-63

2016

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European journal of cancer (1990), 2014-12, Vol.50 (18), p.3077-3088

2014

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review

Cancer treatment reviews, 2014-02, Vol.40 (1), p.86-92

2014

Link zum Volltext

Verfügbarkeit prüfen

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence

Cancer treatment reviews, 2015-03, Vol.41 (3), p.271-276

2015

Link zum Volltext

Verfügbarkeit prüfen

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)

Breast (Edinburgh), 2016-02, Vol.25, p.69-74

2016

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer

European journal of surgical oncology, 2014-10, Vol.40 (10), p.1216-1221

2014

Link zum Volltext

Verfügbarkeit prüfen

CDK4/6 inhibition in early and metastatic breast cancer: A review

Cancer treatment reviews, 2017-11, Vol.60, p.130-138

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

Annals of oncology, 2015-10, Vol.26 (10), p.2141-2149

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Gynecologic oncology, 2022-05, Vol.165 (2), p.223-229

2022

Link zum Volltext

Verfügbarkeit prüfen

Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe

Cancer treatment reviews, 2018-01, Vol.62, p.74-90

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)

Breast cancer research and treatment, 2013-06, Vol.139 (2), p.371-379

2013

Link zum Volltext

Verfügbarkeit prüfen

Gene expression signatures in older patients with breast cancer: A systematic review

Critical reviews in oncology/hematology, 2023-01, Vol.181, p.103884-103884, Article 103884

2023

Link zum Volltext

Verfügbarkeit prüfen

84P Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase I clinical trial

Annals of oncology, 2022-09, Vol.33, p.S578

2022

Link zum Volltext

Verfügbarkeit prüfen

781P Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients

Annals of oncology, 2023-10, Vol.34, p.S527-S527

2023

Link zum Volltext

Verfügbarkeit prüfen

729P Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)

Annals of oncology, 2021-09, Vol.32, p.S732-S733

2021

Link zum Volltext

Verfügbarkeit prüfen

133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial

Annals of oncology, 2022-09, Vol.33, p.S599

2022

Link zum Volltext

Verfügbarkeit prüfen

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

Annals of oncology, 2020-09, Vol.31, p.S501-S502

2020

Link zum Volltext

Verfügbarkeit prüfen

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer

Annals of oncology, 2013-04, Vol.24 (4), p.931-937

2013

Link zum Volltext

Verfügbarkeit prüfen

Higher ER load is not associated with better outcome in stage I-III breast cancer

Annals of oncology, 2019-05, Vol.30, p.iii16-iii17

2019

Link zum Volltext

Verfügbarkeit prüfen

The prognostic role of TGF-β signaling pathway in breast cancer patients

Annals of oncology, 2013-02, Vol.24 (2), p.384-390

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(29)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Oncology
(28)
Female
(26)
Breast Cancer
(17)
Middle Aged
(17)
Adult
(16)
Aged
(16)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Pharmacology. Drug Treatments
(13)
Treatment Outcome
(13)
Antineoplastic Agents
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Breast Neoplasms - Drug Therapy
(10)
Chemotherapy
(10)
Tumors
(10)
Hematology, Oncology And Palliative Medicine
(9)
Breast Neoplasms - Pathology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: A systematic review

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence

Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)

Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer

CDK4/6 inhibition in early and metastatic breast cancer: A review

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)

Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe

Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)

Gene expression signatures in older patients with breast cancer: A systematic review

84P Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase I clinical trial

781P Chemotherapy sensitivity score based on ex vivo 3D tumour testing to predict clinical response for ovarian cancer patients

729P Adoptive T-cell therapy during chemotherapy with or without peginterferon-α (IFNα) in patients with platinum sensitive recurrent epithelial ovarian cancer (EOC)

133O Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial

601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer

LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma

Higher ER load is not associated with better outcome in stage I-III breast cancer

The prognostic role of TGF-β signaling pathway in breast cancer patients

Suchergebnisse filtern